Soft Mist Inhalers Market Size & Share 2026-2035

Soft Mist Inhalers Market Size

The global soft mist inhalers market was estimated at USD 212.9 million in 2025. The market is expected to grow from USD 229.4 million in 2026 to USD 564.6 million in 2035, at a CAGR of 10.5% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is driven by several factors, including the increasing prevalence of respiratory conditions, technological advancements in devices and surge in patient preference for inhalation therapy, among other factors.

Rising prevalence of asthma and COPD, improved lung drug deposition vs. MDIs and rising demand for home-based respiratory care are expected to fuel the industry's growth. Boehringer Ingelheim has a monopoly in the market as other players have a limited industry participation. These players mainly focus on product innovation, geographic expansion, integration of advanced technologies, strong R&D, and collaboration with pharmaceutical and device design players, among other factors.

The market has increased from USD 165.4 million in 2022 and reached USD 198 million in 2024, with a historic growth rate of 9.4%. The rising prevalence of respiratory conditions such as asthma, COPD, and bronchitis worldwide is a significant driving force for market growth. For instance, as per the American Lung Association’s data, in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD (chronic obstructive pulmonary disease, chronic bronchitis, or emphysema) in the U.S. These conditions necessitate efficient inhalation therapy, making soft mist inhalers among the preferred choice for patient treatment.

Additionally, this increasing prevalence contributes to the growing demand for drug delivery devices such as soft mist inhalers, which in turn will fuel the industry growth. Further, these devices play a vital role in ensuring the effective administration of medication, thereby improving patient outcomes and facilitating the advancement of personalized medicine approaches.

Soft mist inhalers (SMIs) are inhalation devices used to deliver medication directly into the lungs in the form of a slow-moving mist. Unlike traditional metered-dose inhalers (MDIs) or dry powder inhalers (DPIs), which deliver medication as aerosols or dry powders, soft mist inhalers produce a fine mist of medication that is propelled by mechanical energy.

Soft Mist Inhalers Market Trends

Soft mist inhalers are increasingly being used for a wide range of respiratory-related indications due to consistent innovation in therapeutic respiratory devices, such as improvements in dose accuracy and portability, among others. These parameters are expected to enhance patient convenience and clinical outcome, thereby driving the market growth.

• The advancements in soft mist inhaler technology have enabled the development of novel formulations and smart inhalers that target specific lung areas and provide optimized drug delivery. These innovative formulations enhance treatment outcomes by ensuring precise drug targeting and efficient absorption in the lungs, resulting in increased product demand in the market.
• In addition, researchers are investigating nanotechnology-based drug delivery systems to improve the effectiveness and safety of medications administered through soft mist inhalers.
• Further, utilizing nano-sized drug particles enhances solubility, bioavailability, and targeted delivery to the respiratory tract, thereby optimizing therapeutic outcomes, minimizing systemic side effects, and reducing the necessary dosage.

Soft Mist Inhalers Market Analysis

Based on product type, the market is segmented into disposable and reusable. The disposable segment accounted for a majority share of 64.7% in 2025. Advancements in aerosol and nozzle technology is anticipated to fuel the segmental growth. The segment is expected to reach USD 349.2 million by 2035, growing at a CAGR of 10% during the forecast period.

• Growth drivers support disposable soft mist inhalers through increasing demand for convenience, infection control, and short-term respiratory management.
• Disposable versions reduce the risk of cross-contamination, have no maintenance requirements, and are preferred in low-resource or high patient-turnover environments.
• Additionally, the development of technologically advanced disposable designs at lower cost with consistent dose delivery has further increased the acceptance of soft mist inhalers by clinicians.
• The reusable segment is anticipated to reach over USD 215.5 million by 2035 with a CAGR of 11.4% over the analysis period. Reusable SMIs may offer opportunities for customization and personalization, allowing patients to choose their preferred medication formulations and adjust dosages as needed. This customization can help improve treatment adherence and patient satisfaction.  
• Moreover, though reusable SMIs may have a higher initial cost compared to disposable inhalers, they can be more cost-effective in the long run. Patients with frequent inhaler use may find it more economical to invest in a reusable device rather than purchasing multiple disposable inhalers over time.

Based on age group, the soft mist inhalers market is classified into adult and pediatric. The adult segment generated the highest revenue of USD 158.9 million in 2025.

• Adults are more likely to be exposed to environmental pollutants, occupational hazards, and lifestyle factors such as smoking, which can increase the risk of developing respiratory conditions. These factors contribute to the higher prevalence of respiratory conditions among the adult population and increase the necessity of utilizing medication inhalers such as soft mist inhalers.
• Additionally, respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis are more commonly found among the adult population category than children, thus leading to an increased reliance and demand for soft mist inhalers within the adult age group.
• The pediatric segment was valued at USD 54 million in 2025. The pediatric market is expanding as rates of childhood asthma are increasing and demand for inhalers requiring minimal inhalation force. Soft mist inhalers effectively resolve pediatric issues due to their ability to provide consistent delivery of dosage through lower velocity and reduced coordination error.
• Additionally, caregivers are increasingly preferring inhalation therapy over taking medication orally, thus providing additional support for inhalation device usage.
• Further, there is a rise in the number of children being diagnosed with asthma, the availability of programs for asthmatic children to manage their asthma better in school age, and an increased emphasis on prescribing medications for children expands the potential population being treated with inhalers, thereby fueling the product demand.

Based on application, the soft mist inhalers market is classified into asthma and COPD. The COPD segment generated the highest revenue of USD 126.5 million in 2025.

• Inhalation therapy is the preferred route of drug administration for managing COPD symptoms, as it allows for direct delivery of medications to the lungs, resulting in faster onset of action and lower systemic side effects compared to oral medications.
• Soft mist inhalers offer a user-friendly alternative to traditional inhalation devices, making them particularly suitable for COPD patients who may have difficulty using other inhalers due to coordination issues or reduced lung function.
• Additionally, soft mist inhalers equipped with user-friendly functionalities like breath-actuation mechanisms and dose counters play a crucial role in enhancing patient adherence to COPD treatment plans. These features simplify the inhalation process and offer visual feedback on medication usage, ultimately improving treatment adherence.
• Further, enhanced adherence translates to better treatment results, fewer exacerbations, and an overall improved quality of life for individuals living with COPD.
• The asthma segment was valued at USD 86.4 million in 2025. Factors driving the growth of asthma include increasing prevalence, early diagnosis, and a preference for fast-acting inhalation therapies. By delivering accurate doses into the patient's lungs via soft mist inhalers, the product also enhances control over asthma symptoms, improves relief from asthma symptoms, and reduces exacerbation of their symptoms.
• Furthermore, factors such as patient preference and technology improvements result in an increase in adherence to prescribed medication among the mild-to-moderate asthma population.
• The ongoing expansion of preventive medication usage, as well as combination inhalers, may help maintain demand for medications used to manage asthma.
• Moreover, current asthma management guidelines stress the importance of using proper techniques for inhaling medication into the lungs, which will encourage the use of advanced inhalation delivery systems over the forecast period.

Based on distribution channel, the soft mist inhalers market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment generated the highest revenue of USD 115.9 million in 2025.

• Hospital pharmacies play a vital role in supplying medications for treating acute respiratory conditions like asthma and COPD exacerbations.
• Soft mist inhalers are often prescribed in hospital settings to administer bronchodilators and other medications promptly, making hospital pharmacies the primary distribution channel for these inhalers.
• Additionally, hospital pharmacies may offer access to specialized soft mist inhalers or formulations that aren't readily found in retail or online pharmacies. These specialized medications might be prescribed for patients with severe or refractory respiratory conditions necessitating advanced treatment options, thereby driving growth in this segment.
• The retail pharmacies segment was valued at USD 69.8 million in 2025. Retail pharmacies benefit from recurring prescriptions, chronic disease management, and patient counseling services. Growth drivers, including patient preference for inhalation therapy and long-term disease prevalence, support consistent refill demand.
• Further, retail availability improves accessibility and convenience, reinforcing adherence. Pharmacist-led education enhances correct device usage, increasing satisfaction and repeat demand.
• The growth of the chronic respiratory disease treatment programs may further add significant growth opportunities for the retail pharmacy business in the future.

Based on end use, the soft mist inhalers market is segmented into hospitals and clinics, homecare settings, and other end-users. The hospitals and clinics segment accounted for the leading market share of 52.2% in 2025.

• Hospitals and clinics offer a range of respiratory care services, catering to both inpatient and outpatient needs through emergency department visits, hospital stays, and outpatient clinic appointments.
• Soft mist inhalers are commonly prescribed in both settings to ensure consistent care for patients with respiratory conditions, making hospitals and clinics the primary end users for such products.
• Additionally, healthcare providers working in hospital and clinic environments may have preferences for specific soft mist inhalers based on clinical evidence, patient characteristics, and formulary considerations.
• Hospitals and clinics typically maintain stocks of medications preferred by physicians to meet the requirements of their patient population, thereby driving the product demand.
• The home care settings segment is anticipated to reach around USD 200 million by 2035 with a CAGR of 10.8% over the analysis period. Home care growth is driven by rising chronic disease management, aging populations, and preference for self-administration.
• Soft mist inhalers enable effective at-home therapy due to ease of use and consistent delivery. Growth drivers, including inhalation preference and device reliability, support long-term adherence.
• Furthermore, home care adoption reduces hospital visits and aligns with broader healthcare decentralization trends.

North America Soft Mist Inhalers Market

The North America market accounted for majority share of 43.7% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 87.8 million in 2025, up from USD 81.9 million in 2024. Pediatric and geriatric patient adoption growth coupled with partnerships between device manufacturers and pharma companies are among the key factors supporting the industry growth.
• There is a growing emphasis on personalized medicine and targeted therapies in North America, including the management of respiratory conditions. Soft mist inhalers allow for precise dosing and delivery of medications, enabling healthcare providers to tailor treatment regimens to individual patient needs.
• Thus, the growing focus on personalized medicine drives demand for soft mist inhalers as part of personalized treatment approaches for respiratory diseases.
• Moreover, reimbursement policies and healthcare coverage in North America often include coverage for inhaler medications, making them more accessible and affordable for patients. Favorable reimbursement policies encourage healthcare providers to prescribe soft mist inhalers as part of comprehensive respiratory treatment plans, driving demand for these devices.

Europe Soft Mist Inhalers Market

Europe accounted for a significant share of the global market and was valued at USD 75.5 million in 2025.

• Sustainability initiatives, an aging population, and a growing focus on environmentally friendly medical devices are all contributing towards the growth of the European market.
• Additionally, regulatory pressures to reduce greenhouse gas emissions related to inhalers (MDIs) are expected to boost the adoption of propellant-free soft mist technology.
• European health systems are focused on improving the efficiency of treatments and adherence through the use of soft mist inhalers because of their accurate dosing ability and less dependency upon technique.

Asia Pacific Soft Mist Inhalers Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 35.5 million in 2025.

• The Asia Pacific region is among the fastest-growing regions due to the increasing prevalence of respiratory diseases, urban air pollution, and the growing smoking rate.
• Regional governments are investing significantly in the respiratory care infrastructure, which is leading to an increase in the availability of inhaled medications.
• Further, patients prefer non-invasive treatments, and there is a growing familiarity with advanced inhalers among medical professionals, both of which may facilitate the adoption of these products.

Latin America Soft Mist Inhalers Market

The Latin American market is anticipated to exhibit remarkable growth during the analysis period.

• Market growth in Latin America is supported by rising asthma and COPD prevalence, improving healthcare infrastructure, and gradual expansion of access to prescription inhalation therapies.
• Urbanization and air pollution increase respiratory disease burden, boosting demand for effective drug delivery devices.
• Furthermore, long-term growth is reinforced by increasing diagnosis rates, healthcare modernization efforts, and patient preference for convenient, inhalation-based therapies over systemic medications.

Middle East and Africa Soft Mist Inhalers Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.

• The MEA market is growing gradually, driven by increasing respiratory disease incidence linked to dust exposure, smoking, and urban pollution.
• Gulf countries lead adoption due to higher healthcare spending, strong hospital infrastructure, and specialist-led prescribing. In addition, soft mist inhalers gain traction in tertiary hospitals due to dosing accuracy and ease of use.
• Moreover, international healthcare collaborations, government investment, and rising demand for chronic disease management support market development.

Soft Mist Inhalers Market Share

The soft mist inhaler industry is a moderately consolidated market due to proprietary technologies and long development timelines. Dominance within this sector is held by established pharmaceutical companies, which retain strong intellectual property portfolios, and an extensive amount of regulatory experience and thus have control of combination products. Competitive advantages are accumulated through differentiated delivery platforms, lifecycle management of branded respiratory medicines, and established relationships with prescribers. The main differentiators between manufacturers include equipment performance, dose consistency, and familiarity with clinical practice.

Additionally, specialized device manufacturers and engineering-focused companies play a critical role by supplying precision pumping systems, actuators, and inhaler platforms. They face high competition based on factors such as the ability to customize products, manufacture according to quality standards, cost-effective manufacturing solutions, and developing partnerships with pharmaceutical companies to create alternate delivery systems. There are high barriers to entry due to the extensive regulatory approval process, device validation requirements, and a lack of experience or expertise in the area of human factors engineering.

Moreover, competition is gradually intensifying as companies pursue reusable designs, sustainability-driven innovation, and emerging-market expansion. The overall environment typically favors manufacturers that have a proven ability in the manufacturing of technical products, have the credibility to obtain device approvals during the regulatory process, and have established a long-term relationship with the chronic respiratory therapeutic trends.

Soft Mist Inhalers Market Companies

A few of the prominent players operating in the global soft mist inhalers industry include:

• Aero Pump GmbH
• Boehringer Ingelheim
• Changzhou DSB Medical Co.
• Merxin Ltd.

• Boehringer Ingelheim

Boehringer Ingelheim leverages proprietary Respimat technology, emphasizes lifecycle management of respiratory brands, expands indications, invests in clinical differentiation, supports physician education, and defends device–drug integration through patents.

• Merxin Ltd.

Merxin Ltd. pursues design-led inhaler development, collaborates with pharmaceutical partners, advances human-factor engineering, prototypes soft mist platforms, and positions itself as an innovation-focused device development partner globally.

Soft Mist Inhalers Industry News

• In March 2024, Boehringer Ingelheim implemented a program to cap out-of-pocket costs for its inhaler products at USD 35 monthly. This initiative aims to reduce costs for patients who are underinsured or uninsured, providing them with more affordable access to essential inhaler products. Additionally, this initiative may enhance the awareness about the product and available buying options as well as improve the company’s reputation in the market. 
• In January 2024, Recipharm AB, Medspray, and Resyca entered into an exclusive license agreement to develop nasally delivered drug products utilizing proprietary soft mist technology. This collaboration aims to advance the development of soft mist nasal delivery devices for single and combination drug products and also expand the company’s positioning in the market.

The global soft mist inhalers market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Disposable
• Reusable

Market, By Age Group

• Adult
• Pediatric

Market, By Application

• Asthma
• COPD

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Market, By End Use

• Hospitals and clinics
• Home care settings
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE